September 27, 2026 · AxonCPT Team · telehealth, clinical practice, ADHD assessment

DEA Telemedicine Rules 2027: A Guide for ADHD Prescribers

Through December 31, 2026, any DEA-registered practitioner can prescribe Schedule II–V medications, including ADHD stimulants, over audio-video telemedicine to a patient they have never seen in person, as long as the other conditions in the rule are met. What applies from January 1, 2027 is not settled yet. The DEA has sent a final “special registration” rule to the White House Office of Management and Budget (OMB) for review, but its text is not public. So telehealth ADHD prescribers need a plan for each of the three likely outcomes, not just one.

Clinician holding a telehealth video visit with an adult patient on a laptop, reviewing medication Photo by Vitaly Gariev on Unsplash

This guide covers what the current rule allows, what the proposed permanent framework would change, and what to do before year-end. It is current as of September 27, 2026. It is not legal advice, so confirm the details with your own counsel and your state board, because state law can be stricter than federal law. For the assessment side of remote care, see our overview of remote vs. in-office ADHD testing. For defensible objective data, see objective ADHD testing with AxonCPT.

What do the current DEA telemedicine rules allow?

The current authority is the Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities, published jointly by DEA and HHS on December 31, 2025 (90 FR 61301, Docket No. DEA-407) [1]. It lets a DEA-registered practitioner prescribe Schedule II–V controlled substances by telemedicine without first doing an in-person medical evaluation, through December 31, 2026, when all of these conditions are met [1]:

  1. The prescription is for a legitimate medical purpose, issued in the usual course of professional practice.
  2. It follows a visit using an interactive telecommunications system, which in practice means audio-video for Schedule II stimulants.
  3. The practitioner’s DEA registration covers the relevant schedule, or the practitioner is exempt from registration.
  4. The prescription meets all other requirements of 21 CFR part 1306.

DEA and HHS said the extension was meant to prevent a “telemedicine cliff” and to give DEA time to finish a permanent set of regulations [1]. The official announcements are on the DEA and HHS press pages [2][3].

What happens on January 1, 2027?

Without a new rule, the default is the Ryan Haight Act of 2008. Under that law, a practitioner may remotely prescribe a controlled substance only after at least one in-person medical evaluation of the patient, unless one of a small set of statutory exceptions applies [1]. The Federal Register text also makes an important point: once one in-person evaluation has taken place, the Ryan Haight remote-prescribing requirements no longer apply to that practitioner–patient relationship, however much time has passed since [1].

Here are the three realistic scenarios as of late September 2026:

Scenario What it would mean for telehealth stimulant prescribing What to do now
A final special registration rule is published before Dec 31 New registration, recordkeeping, and PDMP requirements. The details depend on the final text, which is not yet public. Budget time to apply and to change your workflows. Read the final rule in the Federal Register as soon as it appears.
DEA issues a fifth temporary extension The status quo continues for another period. Keep preparing anyway. The Federal Register text says the extension period also exists to give providers time to come into compliance with future rules [1].
The flexibilities lapse with no replacement New patients would need an in-person evaluation (or a statutory exception) before their first remote controlled-substance prescription. Find out which of your patients on Schedule II medication you have never seen in person, and plan how you would do in-person evaluations.

Where the permanent rule stands

DEA proposed the permanent framework on January 17, 2025, in Special Registrations for Telemedicine and Limited State Telemedicine Registrations (90 FR 6541) [4]. The comment period closed March 18, 2025, and DEA received more than 6,475 comments [1][4]. McDermott Will & Schulte and NASCSA (the national association of state controlled-substance regulators) both report that DEA sent a final rule to OMB’s Office of Information and Regulatory Affairs (OIRA) on August 25, 2026 [5][6]. McDermott notes that OIRA review typically takes up to 90 days, that it can be extended, and that the text of the draft final rule is not yet available [5].

What’s still unknown: the final rule may differ in important ways from the 2025 proposal. The provisions below come from the proposed rule, and you should treat them as a signal of direction, not as requirements [4]:

  • Three registration types. A Telemedicine Prescribing Registration (Schedule III–V), an Advanced Telemedicine Prescribing Registration (Schedule II–V), and a Telemedicine Platform Registration.
  • Who could prescribe Schedule II. The Advanced registration was proposed for psychiatrists, several other physician specialties, and mid-level practitioners who are board certified in treating psychiatric or psychological disorders. That category matters to many PMHNPs.
  • A proposed Schedule II cap. Telemedicine special registration prescriptions would make up less than 50% of a clinician’s Schedule II prescriptions in a calendar month.
  • A proposed same-state requirement. For Schedule II prescriptions, the clinician would be physically located in the same state as the patient. DEA said it might adopt one or both of these Schedule II safeguards.
  • PDMP checks. A nationwide PDMP check was proposed, with a three-year delayed effective date. In the meantime, clinicians would check the PDMPs of the patient’s state, the clinician’s state, and any state that has a PDMP reciprocity agreement with either of those states.
  • Proposed fees. $888 for a special registration, plus $50 for each state telemedicine registration for clinicians.

For a closer look at the proposed registration types, the board-certification condition for PMHNPs, and how to prepare, see DEA special registration for telemedicine, explained, and for the separate Medicare payment rule, see the Medicare telehealth in-person rule for mental health.

Is the Medicare in-person rule the same thing?

No. These rules come from different laws. The Medicare rule governs payment for mental health telehealth, and the DEA rule governs prescribing of controlled substances. According to CMS’s telehealth FAQ (updated February 26, 2026), Medicare’s requirement for an in-person, non-telehealth visit within 6 months before the first mental health telehealth service takes effect only after December 31, 2027 [7]. So a Medicare patient might need no in-person visit for billing in 2027 but still need one for a stimulant prescription, depending on how the DEA question is resolved. State telehealth and prescribing laws are a third layer. For example, APRN authority to prescribe Schedule II drugs varies by state.

How to prepare your practice before December 31

Whatever DEA publishes, these steps will hold up:

  1. Build a patient list. Identify every patient receiving a Schedule II stimulant whom the prescriber has never evaluated in person. These are the patients a lapse would affect first.
  2. Plan in-person capacity. Decide where and how you could do in-person evaluations if they become necessary: your own office, a partner clinic, or scheduled visit days.
  3. Tighten PDMP habits now. The proposed rule relied heavily on PDMP checks [4], and most states already require them for Schedule II prescribing. Document every check.
  4. Make the “legitimate medical purpose” visible in the chart. Every version of the rules, temporary or permanent, requires this [1][4]. The chart should show how the diagnosis was established and how treatment response is being measured.
  5. Watch the primary sources. Set an alert for DEA documents on the Federal Register. Don’t rely on summaries, including this one.
  6. Get advice specific to your practice. Ask healthcare counsel about your states, your registration, and your patient mix, and confirm payer requirements separately.

Why objective data matters more when prescribing remotely

Nothing in the DEA rules requires a continuous performance test (CPT) or any other specific assessment. Still, the direction of regulation is clear: more scrutiny of remote Schedule II prescribing, more recordkeeping, and more emphasis on showing that each prescription has a legitimate medical purpose [1][4]. A chart built only on self-report scales is harder to defend than one that also has standardized, repeatable measurement.

An objective attention measure can’t replace the clinical interview, history, collateral information, or rating scales. What it adds is a dated, norm-referenced data point that can be repeated at each titration step. Our guide to using objective data in ADHD medication titration covers how that works across visits. If you bill for testing, our ADHD testing CPT code guide covers the codes involved and what payers expect in the documentation.

Try it with your next patient. AxonCPT gives you 2 free tests every month — no card required. Send a link, your patient finishes in ~16 minutes from home, and you get a norm-referenced report instantly. Create your free account →

How this looks in practice

Here is a remote workflow that fits under the current rules and under any likely successor:

  1. Intake by video. Clinical interview, history, screening for substance use and other conditions, and a PDMP check, all documented.
  2. Standardized rating scales from the patient and, where possible, an informant.
  3. An objective attention measure. With AxonCPT, you send the patient a link. They complete the test on their own device at home, in about 16 minutes, with no app or login. Scores are compared with age- and sex-matched norms drawn from a 20,000+ reference dataset.
  4. Review the report. It covers five metrics and a Q1–Q4 vigilance breakdown. You can see what the report looks like before you send a test.
  5. Decide and document. Integrate every source, record the diagnostic reasoning, and plan how you will measure response.
  6. Follow up. Retest at dose changes and compare results across visits, alongside patient report.

If you work in a setting where remote testing isn’t appropriate for a particular patient, the same structure works in the office. The point is a consistent, documented process.

Frequently asked questions

Can I keep prescribing Adderall by telehealth after December 31, 2026? Through December 31, 2026, yes, if the conditions of the current temporary rule are met [1]. After that, it depends on whether DEA publishes a final special registration rule, issues another extension, or lets the flexibilities lapse. For patients you have already evaluated in person, the Federal Register text says the Ryan Haight remote-prescribing requirements no longer apply to that relationship [1]. Confirm how your state treats these situations.

Would PMHNPs qualify for the Advanced Telemedicine Prescribing Registration? Under the proposed rule, mid-level practitioners board certified in treating psychiatric or psychological disorders were among those eligible for the Schedule II registration [4]. The final rule’s eligibility criteria are not yet public, and state scope-of-practice limits still apply.

Does a remote CPT count as an in-person evaluation? No. A patient-administered test is an assessment tool, not a medical evaluation, and it does not satisfy any in-person requirement. It adds objective data to the clinical record. It is not a substitute for the clinician’s evaluation.

Does the Medicare telehealth extension through 2027 cover controlled-substance prescribing? No. The CMS in-person requirement for mental health telehealth, delayed until after December 31, 2027, concerns Medicare payment [7]. DEA rules govern controlled-substance prescribing separately.

Start testing your patients with AxonCPT

Whatever DEA finalizes, telehealth ADHD care is heading toward more documentation and more scrutiny. A repeatable, norm-referenced attention measure helps you show how a diagnosis was supported and how treatment is working. AxonCPT gives you 2 free tests every month with no card required, and results arrive as soon as your patient finishes. Create your free AxonCPT account or learn more at axoncpt.com.

References

  1. Drug Enforcement Administration & Department of Health and Human Services. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. Federal Register, 90 FR 61301, December 31, 2025.
  2. Drug Enforcement Administration. DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care. Press release, December 31, 2025.
  3. U.S. Department of Health and Human Services. HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026. Press release, December 2025.
  4. Drug Enforcement Administration. Special Registrations for Telemedicine and Limited State Telemedicine Registrations (proposed rule). Federal Register, 90 FR 6541, January 17, 2025.
  5. McDermott Will & Schulte (via Mondaq). DEA Appears Close To Finalizing Telemedicine Special Registration. September 24, 2026.
  6. National Association of State Controlled Substances Authorities. DEA Gets Closer to Finalizing Telemedicine Special Registration. September 21, 2026.
  7. Centers for Medicare & Medicaid Services. Telehealth FAQ, updated 2/26/26. February 26, 2026.